Related Experiment Video
Updated: Nov 21, 2025
10:25
Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection
Published on: June 5, 2021
5.0K
Development of Coronavirus Treatments Using Neutralizing Antibodies
Saman Fouladirad1, Horacio Bach1,2
1Department of Medicine, University of British Columbia, Vancouver, BC V6T 1Z, Canada.
Microorganisms
|January 16, 2021
Summary
Neutralizing antibodies show promise for treating coronaviruses like COVID-19, offering a potential alternative to supportive care. Further randomized trials are needed to confirm the efficacy of these monoclonal antibodies.
Area of Science:
- Virology
- Immunology
- Infectious Diseases
Background:
- COVID-19, caused by SARS-CoV-2, has led to millions of cases globally.
- Current COVID-19 treatments primarily focus on supportive care, lacking definitive approved therapies.
- Immunotherapy, specifically monoclonal antibodies (mAbs), presents a novel therapeutic avenue.
Purpose of the Study:
- To review existing literature on neutralizing antibodies for coronavirus treatment.
- To summarize in vivo evidence for the therapeutic potential of neutralizing antibodies against coronaviruses.
- To identify the need for further clinical research in this area.
Main Methods:
- Systematic review of articles from PubMed.
- Analysis of studies reporting in vivo results of neutralizing antibodies.
- Focus on evidence related to coronavirus treatment.
Main Results:
- Promising in vivo data exists for neutralizing antibodies against coronaviruses.
- No reviewed studies have progressed to clinical trials for this application.
- Monoclonal antibodies offer potential advantages over traditional serum therapies.
Conclusions:
- Neutralizing antibodies may offer a viable treatment option for COVID-19.
- Randomized controlled trials are essential to establish the clinical utility of neutralizing antibodies.
- Further research is crucial to validate this therapeutic strategy.
